跳至主要内容
临床试验/NL-OMON26628
NL-OMON26628尚未招募不适用

Intra-Operative Visualization and Treatment of Salivary Glands in Sjögren’s Syndrome by Contrast-Enhanced Ultrasound Sialendoscopy (CEUSS): Protocol for a Phase I Single-Center, Single-Arm, Exploratory Study.

Amsterdam UMC, VU Medical Center dep. of Oral and Maxillofacial Surgery and Oral Pathology0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • A diagnosed (by the 2016 ACR-EULAR criteria) primary or secondary Sjögren’s syndrome
  • - Age: =18 years and = 75 years
  • - A remaining salivary flow: UWS=0.02, SWS=0.10 ml/min

排除标准

  • - A remaining salivary flow: UWS<0.02, SWS<0.10 ml/min
  • - When it is not possible to identify and enter the orifice of the salivary duct(s) (determined during T-6)
  • - Acute sialadenitis, severe illness or physical conditions interfering with the intervention
  • - Use of sialogogue medication (i.e. Pilocarpine)
  • - A history of head and neck radiotherapy
  • - Cardiac patients with an (suspected) acute coronary syndrome, recent percutaneous coronary intervention, acute or chronic severe [New York Heart Association (NYHA) class III/IV] heart failure, right-to-left shunts, severe pulmonary hypertension (pulmonary artery pressure >90 mmHg) or uncontrolled hypertension, adult respiratory distress syndrome or severe cardiac dysrhythmias.
  • - Use of Dobutamine. Sonovue should not be used in combination with dobutamine (used for heart failure) in patients with conditions that suggest cardiovascular instability where dobutamine is contraindicated.
  • - Presence of MALT-lymphoma in the major salivary glands

研究者

发起方
Amsterdam UMC, VU Medical Center dep. of Oral and Maxillofacial Surgery and Oral Pathology

相似试验